Clinical Trial Update: DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating DOC1021 dendritic cell immunotherapy for newly diagnosed adult glioblastoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• DOC1021 Dendritic Cell Immunotherapy (DOC1021)

Snippet

Sponsor: Diakonos Oncology Corporation | Conditions: Glioblastoma (GBM) | Phase 2 | Status: RECRUITING